[go: up one dir, main page]

HUP0202150A3 - Use of nitric oxide donors for inducing neurogenesis - Google Patents

Use of nitric oxide donors for inducing neurogenesis

Info

Publication number
HUP0202150A3
HUP0202150A3 HU0202150A HUP0202150A HUP0202150A3 HU P0202150 A3 HUP0202150 A3 HU P0202150A3 HU 0202150 A HU0202150 A HU 0202150A HU P0202150 A HUP0202150 A HU P0202150A HU P0202150 A3 HUP0202150 A3 HU P0202150A3
Authority
HU
Hungary
Prior art keywords
nitric oxide
oxide donors
inducing neurogenesis
neurogenesis
inducing
Prior art date
Application number
HU0202150A
Other languages
English (en)
Original Assignee
Henry Ford Health System Detro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System Detro filed Critical Henry Ford Health System Detro
Publication of HUP0202150A2 publication Critical patent/HUP0202150A2/hu
Publication of HUP0202150A3 publication Critical patent/HUP0202150A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HU0202150A 1999-06-14 2000-06-14 Use of nitric oxide donors for inducing neurogenesis HUP0202150A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13897199P 1999-06-14 1999-06-14

Publications (2)

Publication Number Publication Date
HUP0202150A2 HUP0202150A2 (en) 2002-10-28
HUP0202150A3 true HUP0202150A3 (en) 2003-10-28

Family

ID=22484514

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202150A HUP0202150A3 (en) 1999-06-14 2000-06-14 Use of nitric oxide donors for inducing neurogenesis

Country Status (14)

Country Link
US (1) US8383626B2 (hu)
EP (1) EP1233670B1 (hu)
JP (1) JP2003532622A (hu)
CN (2) CN101310772B (hu)
AT (1) ATE408402T1 (hu)
AU (1) AU782283B2 (hu)
CA (1) CA2377373C (hu)
DE (1) DE60040299D1 (hu)
ES (1) ES2313895T3 (hu)
HU (1) HUP0202150A3 (hu)
IL (1) IL147112A0 (hu)
NZ (1) NZ516513A (hu)
WO (1) WO2000076318A1 (hu)
ZA (1) ZA200110305B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
DE60040299D1 (de) 1999-06-14 2008-10-30 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
EP1469852A4 (en) * 2002-01-04 2009-12-02 Ford Henry Health System NITROGEN DONORS FOR THE TREATMENT OF DISEASE AND INJURY
JPWO2006075642A1 (ja) * 2005-01-12 2008-06-12 味の素株式会社 低酸素応答亢進剤
WO2006128121A2 (en) 2005-05-27 2006-11-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP2194781B2 (en) * 2007-10-04 2021-03-24 Société des Produits Nestlé S.A. Compositions and methods for enhancing cognitive function
US20100233304A1 (en) * 2008-01-04 2010-09-16 Yuanlong Pan Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
US9023890B2 (en) 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
JP2014514248A (ja) * 2011-02-18 2014-06-19 ネステク ソシエテ アノニム 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
PE20142258A1 (es) 2012-04-25 2015-01-15 Takeda Pharmaceutical Compuesto heterociclico nitrogenado
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3310349B1 (en) 2015-06-22 2021-01-13 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4476196A (en) 1983-10-12 1984-10-09 The United States Of America As Represented By The United States Department Of Energy Solid oxide fuel cell having monolithic cross flow core and manifolding
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5226182A (en) 1992-02-04 1993-07-13 Marilyn Tucker Excrement collection and disposal device and method
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
EP0721464A4 (en) 1993-09-01 1998-12-30 Start Technology Partnership NEURON REGULATOR FACTOR FOR PROMOTING NEURON SURVIVAL
CA2175467A1 (en) * 1993-11-02 1995-05-11 David A. Wink, Jr. Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
DE60040299D1 (de) 1999-06-14 2008-10-30 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese

Also Published As

Publication number Publication date
JP2003532622A (ja) 2003-11-05
EP1233670A4 (en) 2004-04-14
CA2377373A1 (en) 2000-12-21
CN101310772A (zh) 2008-11-26
ES2313895T3 (es) 2009-03-16
AU5488200A (en) 2001-01-02
CN101310772B (zh) 2012-02-08
CA2377373C (en) 2011-05-10
ATE408402T1 (de) 2008-10-15
HUP0202150A2 (en) 2002-10-28
IL147112A0 (en) 2002-08-14
NZ516513A (en) 2004-03-26
EP1233670B1 (en) 2008-09-17
CN1370044A (zh) 2002-09-18
EP1233670A1 (en) 2002-08-28
ZA200110305B (en) 2002-11-27
WO2000076318A1 (en) 2000-12-21
US8383626B2 (en) 2013-02-26
DE60040299D1 (de) 2008-10-30
US20110071168A1 (en) 2011-03-24
AU782283B2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
HUP0202150A2 (en) Use of nitric oxide donors for inducing neurogenesis
AU3947902A (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1283702A4 (en) MEDICAL ASSOCIATION ARRANGEMENT AND METHOD OF THE APPLICATION
AU3651002A (en) Seed-preferred regulatory elements and uses thereof
HK1097437A1 (en) Therapeutic use of nitric oxide precursor
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
AU4757901A (en) Matrices containing nitric oxide donors and reducing agents and their use
PL355101A1 (en) Use of h1
EP1207811A4 (en) STAIN OXIDE RELEASE MEDICAL ARTICLES
IL155968A0 (en) Inhalation of nitric oxide
HUP0201763A3 (en) Microreservoir system on the basis of polysiloxanes and ambiphilic solvents
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
DE60003109T2 (de) Strahlmittel und Strahlverfahren
IL147891A0 (en) Topical use of anti-muscarnic agents
HUP0203721A3 (en) Novel hormonal composition and the use thereof
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
EP1222913A4 (en) EPILATOIRES AND AGENTS FOR EXTERNAL USE
HK1069385A1 (en) Heterocyclic compound and medicinal use thereof
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
EP1260211A4 (en) SKIN CARE FOR EXTERNAL USE
HUP0203065A3 (en) Use of nitric oxide for the treatment of airway constriction
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
GB0018887D0 (en) Compound and their therapeutic use
PL350128A1 (en) Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees